Investment Rating - The report assigns a "Buy" rating to the company, indicating a positive outlook for the stock price over the next six months [6]. Core Insights - The company reported a revenue of HKD 1.913 billion for 2024, a slight decrease of 0.56% year-on-year, with a net loss attributable to shareholders of HKD 135 million, compared to a profit in the previous year [1][2]. - The gross margin decreased to 27.58%, down 4.59 percentage points year-on-year, primarily due to price reductions in ophthalmic surgeries and an increase in low-margin dental services [2]. - The company is focusing on expanding its dental business, which saw a revenue increase of 18.50% to HKD 507 million, driven by the mainland's healthcare policies [3][4]. - The company is undergoing a restructuring phase in 2024, with plans to close underperforming facilities while expanding its presence in the Greater Bay Area [4]. Financial Summary - The company expects revenues to grow to HKD 2.179 billion in 2025, with a projected net profit of HKD 75 million, reflecting a significant recovery from the current year's losses [5][10]. - The projected PE ratios for 2025, 2026, and 2027 are 26X, 21X, and 18X respectively, indicating a gradual improvement in profitability [4][10]. - The report highlights a projected gross margin recovery to 30.9% by 2025, suggesting improved operational efficiency [10].